NFKB1 and osteosarcoma: To validatethe mode of action of compound 35, silencing of p65 inthese cell lines was conducted, and treatment with compound 35 increased the sensitivity of the osteosarcoma cells duringmigration and invasion assays, validating compound 35 as a ROS modulator of the NF-κB signaling pathway.